Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-SAFT: Real-world teprotumumab in Chinese thyroid-associated ophthalmopathy
ChiCTR2600119191Phase 4Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of teprotumumab in Graves Orbitopathy (GO), sponsored by Shanghai General Hospital. Primary endpoint: Proptosis response rate (study eye) at week 24. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
teprotumumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2600119191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119191.